An Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3866 When Administered to Subjects With Moderate and Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs MK-3866 (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 06 Dec 2017 Planned initiation date changed from 10 Oct 2017 to 11 Dec 2017.
- 06 Dec 2017 Status changed from not yet recruiting to recruiting.
- 29 Sep 2017 New trial record